-
Canaccord Turns Bullish On Mallinckrodt: 4 Reasons Why
Monday, November 19, 2018 - 12:15pm | 501Read More...A Canaccord Genuity analyst came away from a meeting with Mallinckrodt PLC (NYSE: MNK)'s executive team with an upbeat forecast for the pharma company's near-term prospects. The Analyst Analyst Dewey Steadman upgraded Mallinckrodt from Hold to Buy and increased the price target...
-
Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
Wednesday, March 21, 2018 - 4:36pm | 369Read More...CARDIOME PHARMA CORP (NASDAQ: CRME) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. The Analyst Canaccord Genuity's Dewey Steadman maintains a Buy rating on Cardiome's stock with an unchanged...
-
Adcom Outcome For Lipcocine's Testosterone Drug Punctures Stock; Canaccord Downgrades
Thursday, January 11, 2018 - 3:49pm | 327Read More...Lipocine Inc (NASDAQ: LPCN), a pharma company focusing on men's and women's health, announced Wednesday the FDA's Bone, Reproductive and Urologic Drugs Advisory Committee, voted against the benefit/risk profile of TLANDO, its oral testosterone product candidate for testosterone...
-
Warner Chilcott is JP Morgan's Top Pick Within Specialty Pharmaceuticals (WCRX)
Thursday, June 10, 2010 - 11:02am | 151Read More...Warner Chilcott (NASDAQ: WCRX) will likely be added to the Russell 1000 on Friday, June 11 and should serve as an NT catalyst for the shares. An inclusion in the S&P 500 later this year is also possible. JP Morgan analysts Chris Schott, Dewey Steadman, and Jessica Fye rate WCRX Overweight. The...
-
Forest Laboratories (FRX) Shares Climb 5.6%
Tuesday, May 18, 2010 - 6:09pm | 115Read More...Shares of Forest Laboratories Inc. (NYSE: FRX) closed Tuesday trading up 5.65% at $27.67 per share. Forest Laboratories Inc. opened Tuesday morning at $27.87 per share, and didn't show many dramatic movements for the rest of the day, trading between $27.22 and $28.14 per share. Volume of nearly 15...
-
J.P. Morgan Rates Forest Laboratories (FRX) Underweight
Tuesday, May 18, 2010 - 9:50am | 190Read More...J.P. Morgan analysts Chris Schott, Dewey Steadman and Jessica Fye maintained their rating of Underweight for shares of Forest Laboratories, Inc. (NYSE: FRX), with a price target of $27 per share. The analysts said that it's unlikely that Daxas will prove to be a meaningful earnings driver for...
